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Summary 
Established primary prevention strategies of cardiovascular diseases are based on understanding of 
risk factors, but whether the same risk factors are associated with atrial fibrillation (AF) remains 
unclear.  
We conducted a systematic review and field synopsis of the associations of 23 cardiovascular risk 
factors and incident AF, which included 84 reports based on 28 consented and 4 electronic health 
record cohorts of 20,420,175 participants and 576,602 AF events. We identified 3 to 19 reports per 
risk factor and heterogeneity in AF definition, quality of reporting, and adjustment. We extracted 
relative risks (RR) and 95% confidence intervals [CI] and visualised the number of reports with 
inverse (RR [CI]<1.00), or direct (RR [CI]>1.00) associations.  For hypertension (13/17 reports) and 
obesity (19/19 reports), there were direct associations with incident AF, as there are for coronary 
heart disease (CHD). There were inverse associations for non-White ethnicity (5/5 reports, with RR 
from 0.35 to 0.84 [0.82-0.85]), total cholesterol (4/13 reports from 0.76 [0.59-0.98] to 0.94 [0.90-
0.97]; 8/13 reports with non-significant inverse associations), and diastolic blood pressure (2/11 
reports from 0.87 [0.78-0.96] to 0.92 [0.85-0.99]; 5/11 reports with non-significant inverse 
associations), and direct associations for taller height (7/10 reports from 1.03 [1.02-1.05] to 1.92 
[1.38-2.67]), which are in the opposite direction of known associations with CHD.  
A systematic evaluation of the available evidence suggests similarities as well as important 
differences in the risk factors for incidence of AF as compared with other cardiovascular diseases, 
which has implications for the primary prevention strategies for atrial fibrillation. 
 
Key words 
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What is known on this topic:  
 Atrial fibrillation is the world’s most common heart rhythm disorder, and leading cause of fatal 
and disabling strokes, yet current clinical practice guidelines offer no recommendations for 
primary prevention in individuals without pre-existing cardiovascular disease.  
 
 Established primary prevention strategies of other cardiovascular diseases (e.g. coronary heart 
disease and stroke), are based on understanding of risk factors, but whether the same risk 
factors are associated with incident atrial fibrillation remains unclear. 
 
 There is a lack of systematic reviews and field synopses of risk factors for atrial fibrillation 
among general populations and populations initially free from diagnosed CVD. 
 
What this paper adds: 
 A systematic evaluation of evidence from 28 consented and 4 electronic health record cohorts 
confirms the importance of hypertension and obesity, but suggests important differences in the 
risk factors for incident atrial fibrillation as compared with other cardiovascular diseases.  
 
 Non-white ethnicity, shorter height, higher cholesterol and higher diastolic blood pressure all 
showed some evidence of being associated with lower risk of incident AF.  This contrasts with 
the known associations of these risk factors in the opposite direction with coronary heart 
disease. 
 
 The evidence for the widely held clinical opinion that alcohol use is associated with incident AF 
in the primary preventative setting was modest.  
 
 These findings provide a systematic basis on which to direct research into the primary 
prevention of AF. 
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Introduction 
Atrial fibrillation (AF) is the world’s most common heart rhythm disorder, affecting 33.5 
million people globally in 2010.(1) AF accounts for 1 in 4 ischaemic strokes,(2) doubles the risk of 
death,(3) places an economic burden on healthcare systems,(4) and is projected to affect twice as 
many people by 2050.(5, 6) Yet to date, there have been no clinical trials of healthy participants 
without cardiovascular disease (CVD), and with AF as the primary outcome.(7) The focus of trials 
has instead been on prevention of stroke and thromboembolism after diagnosis of AF. Community 
screening programmes for detection of AF,(8) are also designed to identify patients at high risk of 
stroke and thromboembolism, and do not identify those who are at an initially high risk of later 
developing AF. Thus, current clinical guidelines make no recommendations for the primary 
prevention of AF itself, among people without CVDs.(9-11) 
Established primary prevention strategies of other CVDs, such as coronary heart disease 
(CHD),(12) and stroke,(13) are based on understanding of risk factors, but the extent to which the 
same risk factors are associated with the incidence of AF is not fully understood. Ultimately, it is not 
known whether existing CVD prevention strategies can also work in preventing AF, or whether there 
may be important clinical differences. In synthesising available evidence the conventional (near 
universal) approach is to examine risk factors one at a time. Single risk factor systematic reviews 
and meta-analyses have been carried out for alcohol,(14-16) C–reactive protein,(17) diabetes 
mellitus,(18) obesity,(19) physical activity,(20, 21) and renal function(22) in relation to AF risk.  Each 
of these reviews uses non-identical methods, for example varying in the extent to which incident AF 
is analysed among people free from pre-existing CVD.  While there is an important ongoing role for 
the vertical approach of a single risk factor meta-analysis (particularly if methods can be aligned), 
there is also a complementary role for a horizontal ‘field synopsis’ approach across multiple 
potential risk factors. The term field synopsis is defined as a systematic evaluation of evidence in 
which the (i) overall amount, (ii) extent of replication, and (iii) protection from bias is considered 
across the whole field.(23, 24)  One advantage of a field synopsis in multifactorial diseases is to 
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provide an unbiased empirical basis for prioritising further research into risk factors with preventive 
potential.  
We therefore conducted a systematic review and field synopsis of the associations of a wide range 
of demographic, behavioural, and biological CVD risk factors and incidence of AF in general 
populations and populations initially free from diagnosed CVD. Field synopses’ of cumulative 
evidence,(23, 24) are common in genetics but have seldom been applied in the context of 
preventive medicine. Our objectives were (i) to determine the amount of evidence for each risk 
factor, (ii) to evaluate the extent to which each risk factor shows concordant or discordant 
associations with AF incidence across independent study populations, and (iii) to systematically 
appraise the quality of the observational evidence across the field of AF prevention research. 
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Methods 
Our approach to the search, selection, data collection and analysis of reports was 
systematic, and guided by the Preferred Reporting Items for Systematic reviews and Meta-Analyses 
(PRISMA) checklist.(25)  
Search strategy 
We queried the PubMed database using the search terms listed in appendix p 3, for original 
research reports that were published in English up to 1 October 2015; involving prospective, 
population based cohorts that were either initially free from diagnosed CVD at baseline or were 
general population cohorts in which the proportion of people with diagnosed CVD at baseline was 
low reflecting prevalence in the general population. Cohorts were of any age, and without prior AF; 
and investigated the association between “risk factors” and incident AF, over any follow–up period, 
and using Cox proportional hazards or Poisson regression models adjusted or stratified for age and 
sex as a minimum. We shortlisted 23 cardiovascular risk factors (listed in table 1) for review, based 
on clinical relevance as an established predictor or treatment target in the prevention of CVD,(12) or 
on clinical opinion of an association with AF,(9) and on expert consensus between authors. 
Reference lists of identified reports, existing reviews and meta–analyses (which were not restricted 
to prospective population based cohorts: alcohol,(14-16) C–reactive protein,(17) diabetes 
mellitus,(18) obesity,(19) physical activity,(20, 21) and renal function(22)), were hand–searched for 
additional reports. Two out of three authors (JW, SH, VA) reviewed the inclusion of each report 
based on title, then abstract, then full–text. Disagreements were resolved by joint full–text review 
with a third independent reviewer (RH). 
 
Data extraction 
From each report the following information was extracted: design of cohort (consented 
participant cohort with research measures at baseline and follow up, or electronic health record 
(EHR) cohort in which anonymised data collected as part of usual clinical care was used for 
baseline and follow–up measures), country, sample size (number of participants at baseline) and 
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number of AF events over follow–up (based on the highest figure reported), age range, proportion of 
female participants, mean or median follow–up, methods of AF ascertainment, risk factor definition, 
statistical model, and risk factors used in adjustment. We extracted data on whether cardiovascular 
events, prevalent at baseline and incident during follow–up and preceding AF were accounted for. 
For each risk factor, we extracted adjusted relative risks (RR), and 95% confidence intervals [95% 
CI]. Where there were multiple RR reported within a publication, or across multiple publications from 
the same cohort, we selected the most adjusted estimate, modelled with the highest number of AF 
cases. 
Summary and visualisation of risk factor associations 
We summarised the overall results of the field of cohort epidemiology of AF by plotting the 
number of reports with inverse (RR<1.00), null or mixed (RR=1.00 or shows opposite associations 
among subpopulations), or direct relationship (RR>1.00) with AF incidence. We regarded the 
association as significant if the 95% CI did not cross unity. Unless stated, RR are given as originally 
reported. For each factor, we then plotted the RR and 95% CI using R–3.2.0 (CALIBERdatamanage 
package, available at: caliberresearch.org). 
Summary and visualisation of quality of reporting and analysis 
We summarised the quality of reporting by completeness of the items listed in the above 
data extraction section (items not reported (NR) are clearly indicated in tables and figures). We 
summarised the quality of analysis by assessment of the number (%) of adjustment made for the 23 
risk factors, and whether adjustment was made for 6 standard CVD risk factors (age, sex, smoking, 
blood pressure, lipids and diabetes mellitus), and for prevalent and incident CVD events. We 
visualised these as “Swiss cheese” plots.(26) 
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Results 
Characteristics of included reports 
73 out of 2777 publications were included (figure S1: appendix p 4) with 84 reports on 32 
cohorts from 10 countries and 20,420,175 participants.(16, 27-98) As table 2 shows, 28 (87.5%) 
cohorts involved consented participants with 39,900 (6.9%) events, and 4 cohorts (12.5%) were 
EHR–based with 536,702 (93.1%) events. AF events were ascertained from a research 
electrocardiogram (40 reports (47.6%)), diagnosis codes from medical records (60 reports (71.4%)), 
or using a combination of both methods (24 reports (28.6%)). As table S1 (appendix pp 5–7) shows, 
17 reports (20.2%) described using two out of four types of medical records (i.e. general 
practitioner, hospital care, prescriptions, or mortality records), but no report used three or all four 
types combined. 
 
Quality of reporting 
Age range was not reported in 30 reports (35.7%), mean or median follow–up in 18 reports 
(21.4%), and risk factor definition was not reported in 9 reports (10.7%). Information was 
consistently reported on country, sample size, female participants, and AF events. 
Quality of analysis  
Overall, 63 reports (75.0%) lacked adjustment for all six standard CVD risk factors (table S2: 
appendix pp 8–9). Age was adjusted for in 84 reports (100.0%), sex in 80 reports (95.2%), smoking 
in 49 reports (58.3%), blood pressure in 63 reports (75.0%), lipids in 32 reports (38.1%), and 
diabetes mellitus in 59 reports (70.2%). The total number of adjustment factors ranged from 2–14 
factors, with a median of 8 factors. There was lack of adjustment for prevalent CVD in 30 reports 
(35.7%), and for incident CVD in 69 reports (82.1%). 
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Associations of 23 risk factors and incidence of AF 
A summary of the heterogeneity of associations of 23 risk factors and incidence of AF are 
visualised in figure 1, and for each factor separately in figures 2–6 and S2–S19 (appendix pp 12–
29). There was no evidence of small study bias.  
Demographic factors 
For age, all 15 reports showed significant direct associations, but these were 
heterogeneous. RR [95%CI] ranged from 1.02 [1.01–1.03] to 1.14 [1.10–1.18] for every 1–year, 
from 1.43 [1.29–1.59] to 1.65 [1.57–1.74] for every 5–year, from 1.09 [1.09–1.09] to 2.35 [2.03–
2.72] for every 10–year, and from 1.36 [1.27–1.45] to 4.34 [3.72–5.07] for every standard deviation 
(NR) year increase in age (figure S2).(28, 32, 35, 37, 43, 47, 50, 55, 67, 70, 88, 90, 94, 98) For men 
(compared to women), 1 report showed a significant inverse association (0.70 [0.50–0.90]),(79) 2 
reports were inverse but non-significant  (from 0.95 to 0.96),(88, 98) and 8 reports showed 
significant direct associations (from 1.45 [1.29–1.63] to 1.90 [1.58–2.29]) (figure S3).(37, 43, 47, 50, 
55, 70, 94) For African American, Asian, Chinese, Hispanic and Non-Hispanic Black (compared to 
White) ethnicities, all 5 reports showed significant inverse associations (from 0.35 [NR–NR] to 0.84 
[0.82–0.85]).(28, 44, 85, 92) Only 1 country reported estimates for the association of ethnicity and 
incidence of AF (figure 2). For socio–economic status, 2 reports showed significant inverse 
associations, 3 reports were inverse but non-significant, and 1 report showed a mixed association 
(see appendix p 10 and figure S4 for further details). 
 
Health behaviours 
For current smoking, 1 report was inverse but non-significant (0.78),(35) 1 report showed a 
mixed association,(47) 5 reports were direct but non-significant (from 1.01 to 1.20),(54, 56, 70, 83, 
88) and 6 reports showed significant direct associations (from 1.32 [1.19–1.46] to 2.00 [1.40–2.80]) 
(figure S5).(28, 37, 40, 47, 78, 79) For physical activity, 3 reports showed significant inverse 
associations, 4 reports were inverse but non-significant, 2 reports showed null or mixed 
associations, and 2 reports showed significant direct associations (see appendix p 10 and figure 
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S6). For alcohol intake in drinks per day or week, in grams per day or week, or for current alcohol 
drinkers, 2 reports showed significant inverse associations (from 0.65 [0.45–0.94] to 0.96 [0.93–
0.99]),(53, 83) 1 report was inverse but non-significant (0.97),(46) 1 report showed a null 
association,(28) 3 reports were direct but non-significant (from 1.04 to 1.20),(35, 70, 79) and 3 
reports showed significant direct associations (from 1.39 [1.22–1.58] to 2.90 [1.61–5.23]).(16, 64, 
88) All 10 alcohol reports defined alcohol intake differently, and as shown for the 3 direct alcohol 
associations, the increased risk of developing AF was only among the highest alcohol intake 
categories (figure 3). 
 
Blood pressure 
For every 10–22mmHg increase in systolic blood pressure, or systolic blood pressure 
≥160mmHg, 1 report showed a null association,(79) 5 reports were direct but non-significant (from 
1.01 to 1.24),(35, 47, 55, 83, 84) and 8 reports showed significant direct associations (from 1.14 
[1.05–1.25] to 2.63 [1.83–3.78])( figure S7).(46, 47, 50, 56, 65, 69, 90, 91) For every 10–11mmHg 
increase in diastolic blood pressure, or diastolic blood pressure ≥95–100mmHg, 2 reports showed 
significant inverse associations (from 0.87 [0.78–0.96] to 0.92 [0.85–0.99]),(35, 50, 69) 5 reports 
were inverse but non-significant (from 0.82 to 0.99),(36, 47, 55, 83, 84, 91) 2 reports were direct but 
non-significant (from 1.02 to 1.23),(40, 47, 65) and 2 reports showed significant direct associations 
(from 1.24 [1.10–1.40] to 2.02 [1.20–3.41]).(44, 46, 90) No EHR cohorts reported estimates for the 
association of diastolic blood pressure and incidence of AF (figure 4). For hypertension, 1 report 
was inverse but non-significant (0.93),(88) 3 reports were direct but non-significant (from 1.21 to 
1.37),(35, 55, 79) and 13 reports showed significant direct associations (from 1.28 [1.08–1.51] to 
2.60 [1.60–4.40]) (figure S8).(28, 31, 37, 40, 47, 50, 56, 67, 70, 87, 91, 98) 
 
Lipid profile 
For every 10–50mg/dl increase in total cholesterol, or total cholesterol ≥220–280mg/dl, 4 
reports showed significant inverse associations (from 0.76 [0.59–0.98] to 0.94 [0.90–0.97]),(32, 47, 
53, 61) 8 reports were inverse but non-significant (from 0.57 to 0.99),(35, 41, 47, 56, 67, 71, 83, 88) 
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and 1 report was direct but non-significant (1.13).(71) Both inverse and direct associations were 
shown in the 3 total cholesterol reports that adjusted for prevalent and incident CVD events (figure 
5). For every 10–40mg/dl increase in low–density lipoprotein cholesterol, or low–density lipoprotein 
cholesterol ≥150mg/dl, 2 reports showed significant inverse associations (from 0.72 [0.56–0.92] to 
0.92 [0.88–0.96]),(32, 61) 4 reports were inverse but non-significant  (from 0.85 to 0.95),(41, 55, 71, 
83) and 1 report was direct but non-significant (1.15) (figure S9).(71) For every 15mg/dl increase in 
high–density lipoprotein cholesterol, or high–density lipoprotein cholesterol ≥60mg/dl, 5 reports 
were inverse but non-significant (from 0.85 to 0.98),(32, 47, 71) 2 reports showed null or mixed 
associations,(41, 47) and 3 reports were direct but non-significant (from 1.01 to 1.16) (figure 
S10).(61, 67, 83) For triglycerides, 3 reports were inverse but non-significant, 1 report showed a 
mixed association, 2 reports were direct but non-significant, and 3 reports showed significant direct 
associations (see appendix p 10 and figure S11). 
 
Diabetes mellitus, renal function 
For diabetes mellitus (type unspecified), 2 reports were inverse but non-significant (from 
0.86 to 0.98),(83, 98) 8 reports were direct but non-significant (from 1.02 to 1.49),(37, 47, 54, 56, 
58, 67, 70) and 6 reports showed significant direct associations (from 1.17 [1.16–1.19] to 1.80 
[1.30–2.60]) (figure S12).(28, 40, 50, 79, 88, 95) For renal function, 3 reports were inverse but non-
significant, 5 reports were direct but non-significant, and 3 reports showed significant direct 
associations (see appendix p 11 and figure S13). 
Anthropometric factors 
For every 1–10cm increase in height, or height ≥173cm, 3 reports were direct but non-
significant (from 1.14 to 1.17),(47, 67, 70) and 7 reports showed significant direct associations (from 
1.03 [1.02–1.05] to 1.92 [1.38–2.67]),(34, 46, 47, 53, 56, 79, 89) (figure 6). For weight, all 8 reports 
showed significant direct associations (see appendix p 11 and figure S14). For every 1–10kg/m2 
increase in body mass index, or body mass index ≥25–30kg/m2, all 19 reports showed significant 
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direct associations (from 1.04 [1.02–1.05] to 2.24 [1.41–3.58]) (figure S15).(28, 31, 34, 37, 39, 48, 
55, 56, 60, 67, 70, 76, 79, 81, 83, 88-91) 
 
Inflammatory biomarkers  
For C–reactive protein, 4 reports were direct but non-significant, and 4 reports showed 
significant direct associations (see appendix p 11 and figure S16). For fibrinogen, 2 reports were 
inverse but non-significant, 1 report was direct but non-significant, and 3 reports showed significant 
direct associations (see appendix p 11 and figure S17). 
Thyroid function, autoimmune disease  
For every 1.0mU/L decrease in thyroid stimulating hormone, or thyroid stimulating hormone 
<0.10–0.45mU/L, 1 report was inverse but non-significant (0.34),(82) 5 reports were direct but non-
significant (from 1.06 to 2.85),(51, 77, 82) and 2 reports showed significant direct associations (from 
1.41 [1.25–1.59] to 3.10 [1.70–5.50]) (figure S18).(72, 96) For autoimmune diseases, all 3 reports 
showed significant direct associations (see appendix p 11 and figure S19). 
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Discussion 
To our knowledge this is the first example of a field synopsis evaluating associations across 
multiple risk factors and disease incidence. We systematically evaluated 84 reports from 32 
independent cohorts for the impact of 23 cardiovascular risk factors on incidence of AF. Unlike 
previous overviews of AF risk factors,(10, 99) we focussed exclusively on primary prevention among 
populations initially free from diagnosed CVD or general populations in which baseline levels of 
CVD reflected prevalence in the general population. We found some evidence that ethnicity, height, 
diastolic blood pressure and serum cholesterol, are associated with AF incidence in opposite 
directions to their known associations with CHD and stroke. Furthermore we found only modest 
evidence for the widely held clinical opinion that excess alcohol is associated with risk of AF. Taken 
together our findings suggest that primary prevention strategies for AF may require some different 
elements from the current approaches used for other CVDs.  
Concordant associations 
For some risk factors – hypertension, and higher body mass index – there were consistent, 
direct associations with incident AF, as there are for CHD. This could reflect a causal link with AF, 
or that the risk factor causes CHD, which in turn causes AF. Surprisingly, we found that only 3 (out 
of 14) reports investigating the association between systolic blood pressure and incident AF 
accounted for both prevalent and intercurrent incident cardiovascular events, and only 1 of which 
reported a significant direct association. Several post hoc analyses of trials have suggested a 
possible benefit of ACE/ARB–inhibitors,(100) and other blood–pressure lowering medications,(101) 
for prevention of AF. However, we demonstrate that across all 23 risk factors, the available 
observational evidence does not fully consider a mechanism or confounding of reported 
associations by intercurrent CHD. 
Current clinical guidelines include alcohol in a list of potentially “reversible” causes of AF, but 
acknowledge that there is no evidence to suggest addressing any of these is effective in preventing 
AF.(9) We found a small number of reports (3 out of 10) suggesting a direct association between 
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alcohol intake and AF incidence. This is in contrast to three existing alcohol reviews (Samokhvalov, 
et al. (2010) to April 2009,(14) Kodama, et al. (2011) to January 2009,(15) and Larsson, et al. 
(2014) to January 2014(16)), which have reported dose–response relationships. There are several 
possible explanations as to why our findings differ. Unlike the previous alcohol reviews, ours 
considers (i) only prospective studies (Samokhvalov, et al. and Kodama, et al. included 
retrospective studies; similarly Larsson et al. focused on prospective studies), (ii) only general 
population cohorts (Larsson, et al. included one cohort with pre-existing CVD), (iii) only incident AF 
events (Kodama, et al. included studies on AF recurrence), (iv) only estimates from Cox or Poisson 
regression (Samokhvalov, et al., Kodama, et al., and Larsson, et al. all included estimates from 
logistic regression), (v) only the most adjusted alcohol estimate per cohort (Samokhvalov, et al. 
included the study with the most comprehensive alcohol data, while Larsson, et al. did not report an 
approach to selecting from multiple estimates per cohort), and lastly (vi) our more recent review and 
more inclusive field synopsis method includes 8 reports that have not been included in the previous 
reviews.(28, 35, 46, 53, 70, 79, 83, 88) Based on the 3 direct alcohol associations we identified, the 
increased risk of developing AF was confined to the highest alcohol intake levels, as opposed to 
there being a J–shaped or dose–response relationship. Overall, our findings indicate that at present, 
there is limited consistent evidence on which recommended alcohol intake levels for primary 
prevention of AF could be based.  
Discordant associations 
We found some evidence that white ethnicity, taller height, lower total cholesterol and lower 
diastolic blood pressure might confer a higher risk of incident AF, which is in the opposite direction 
to their known associations with incident CHD.(12) Our findings regarding cholesterol suggest that 
reducing cholesterol may not be relevant for the primary prevention of AF, and are in line with an 
existing meta–analysis of trial evidence, which did not support the role of statins for prevention of 
AF in participants with underlying CVD.(102) Previously, it been demonstrated that blood pressure 
has markedly different associations with the incidence of twelve individual cardiovascular diseases 
(not including AF).(103) We now provide some, albeit mixed, evidence that this may also be the 
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case for AF. The direct and inverse associations shown for systolic and diastolic blood pressure 
respectively, may indicate high pulse pressure, which is a marker of arterial stiffness and is more 
prevalent in older populations.(104) Two earlier studies found an association between pulse 
pressure and incidence of AF,(69, 84) however pulse pressure was not considered in this review as 
its clinical utility is not well defined.(105)  
Clinical implications 
The observational evidence summarised here suggests that programmes for AF primary 
prevention may need to differ slightly from those which have guided clinicians and public health 
practitioners in the primary prevention of other CVDs. Existing management strategies to tackle 
obesity, smoking, alcohol and hypertension may have a role but the current evidence is insufficient 
to design AF specific interventions. The risk factors included in available prediction tools for 5 or 10 
year risk of incident AF are supported by our systematic review, and these tools should be used 
more frequently in clinical practice.(47, 70) Such risk prediction tools could identify high–risk 
individuals for inclusion in primary prevention trials in AF, where there is the largest knowledge gap. 
Overall characteristics of the field 
Overall, we found a relatively “young” field, which has been rapidly expanding over the last 
five years (see figure S20: appendix p 30). Although we included 32 cohorts of 20 million 
participants and 600,000 AF events, we found a limited number of reports (between 3 and 19) per 
risk factor. Although we identified some efforts at pooling studies (e.g. the CHARGE–AF consortium 
of 5 cohorts, 3 countries, and 1771 AF events(47)), the amount of evidence available is markedly 
smaller than the scale of cohort evidence available on risk factors for CHD or stroke incidence (e.g. 
the emerging risk factor collaboration consists of over 100 cohorts(106)). Next, we found that the AF 
field is beginning to span both consented population and electronic health record studies, with all 7 
EHR reports published in 2011–2015. In the era of “big data” research, EHRs offer the potential for 
studying associations at much larger scale, at population–level, in comparison with other risk 
factors, and across a wide range of diseases.(107) None of the EHR cohorts analysed continuous 
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measures of blood pressure, lipids, body mass index, or renal function. Linking data from consented 
population and EHR sources therefore represents an important research opportunity to investigate 
risk factors for AF at depth and at scale. Finally, we found considerable heterogeneity in study 
design and reporting, and a lack of consistent approach to adjustment for other risk factors 
(visualised as a “Swiss cheese”). Field synopses allow for differences in study designs, however in 
order to further inform primary preventive programmes and estimate the precision effect of each risk 
factor in meta-analyses; there is a need for large–scale strategic co–ordination of the field of AF 
prevention research. 
Strengths and Limitations 
The principle strength of our study – evaluation across a comprehensive range of risk factors 
– is also the principle weakness. In order to evaluate the breadth of the field there is a necessary 
restriction in the depth of analysis of any one risk factor, or relations between them. As we only 
searched the PubMed database, it is possible that we may have missed relevant studies. We 
conducted a sensitivity analysis for the year 2013, and found no further eligible studies in EMBASE, 
which is consistent with other reports showing limited additional value of searching biomedical 
databases beyond PubMed.(108, 109) There are of course other publications in support of 
searching multiple databases to identify further studies.(110, 111) However, as we did not perform 
meta-analysis, we have not introduced any computational bias in to the present work and therefore 
consider our results and conclusions unlikely to change. Field synopses provide a systematic 
foundation, unbiased by a particular interest in one or more risk factors,(112) for hypothesis 
generation and further research. One example of this would be to evaluate the extent to which the 
findings in relation to ethnicity, height and lipids(113) might be inter–related.  
Conclusions 
A systematic evaluation of the available evidence suggests similarities as well as important 
differences in the risk factors for AF as compared with other cardiovascular diseases. This has 
implications for the primary prevention of atrial fibrillation. 
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Table and figures legends  
Table 1. 23 cardiovascular risk factors investigated for their associations with incident atrial 
fibrillation in populations based cohorts  
Table 2. Characteristics of included reports, sorted by cohort and number of atrial fibrillation 
events 
Figure 1. Associations of 23 risk factors for incidence of atrial fibrillation according to 
number of reports, number of events, and direction of association 
Figure 1 legend: AF – atrial fibrillation, EHR – electronic health record, [ ] – referent category, sig. – significant. 
Risk factor and reference group definitions are detailed in individual risk factors plots (figures 2–6 and S2–S19). 
Each dot represents one report, colour–coded to indicate the direction of association, and in order of most extreme 
inverse to most extreme direct point estimate. Dots are scaled by the number of AF events (<100, 100–<1000, 1000–
<10000, 10000–<100000, or ≥100000). References correspond to each dot from left to right sequence. Associations are 
classified as inverse (relative risk (RR) <1.00), null or mixed (RR=1.00 or show opposite associations among 
subpopulations), or direct (RR>1.00). Association were regarded as significant if the 95% CI did not cross unity. 
 
 
Figure 2. Association of ethnicity and incidence of atrial fibrillation: 5 reports from 1 country 
with 386 115 events 
Figure 2 legend: EHR – electronic health record, age range in years, follow–up in years (mean, median, or maximum), 
AF – atrial fibrillation, CI – confidence interval, N/23 – number (of factors) out of 23, CVD – cardiovascular disease, SD – 
standard deviation, NR – not reported, USA – United States of America, ● – yes, ○ – no, -- – not applicable. 
Risk factor adjustment refers to whether adjustment was made for the 23 risk factors under review, 6 CVD risk factors, 
and prevalent and incident CVD events. Example: ARIC adjusted for 5/23 risk factors, age, sex, blood pressure (i.e. any of 
systolic blood pressure, diastolic blood pressure, hypertension, or blood pressure lowering medication), and diabetes 
mellitus, but not smoking or lipids (i.e. any of total cholesterol, low–density lipoprotein cholesterol, high–density lipoprotein 
cholesterol, triglycerides, hyperlipidaemia, or lipid lowering medication), and prevalent, but not incident CVD events. 
For cohort abbreviations see table 2. 
 
p 25 (28) 
Figure 3. Association of alcohol intake and incidence of atrial fibrillation: 10 reports from 5 
countries with 18 997 events 
Figure 3 legend: see figure 2 abbreviations, and g – grams, (w) – women, (m) – men. 
Figure 4. Association of diastolic blood pressure and incidence of atrial fibrillation: 11 
reports from 7 countries with 4796 events 
Figure 4 legend: see figure 2 abbreviations, and mmHg – millimetres of mercury. 
Risk factor adjustment for BP in this instance refers to whether systolic blood pressure, hypertension, or blood pressure 
lowering medication were adjusted for. 
Figure 5. Association of total cholesterol and incidence of atrial fibrillation: 13 reports from 8 
countries with 7129 events 
Figure 5 legend: see figure 2 abbreviations, and mg/dl – milligrams per decilitre, mmol/l – millimoles per litre. 
Risk factor adjustment for lipids in this instance refers to whether low–density lipoprotein cholesterol, high–density 
lipoprotein cholesterol, triglycerides, hyperlipidaemia, or lipid lowering medication were adjusted for. Total cholesterol 
reported as mmol/l for CHS, GPPS, TS and BHS was converted to mg/dl using the conversion 1mmol/l = 38·66976 mg/dl. 
Figure 6. Association of height and incidence of atrial fibrillation: 10 reports from 6 countries 
with 7181 events 
Figure 6 legend: see figure 2 abbreviations, and cm – centimetres, (m) – men, (w) – women. 
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Table 1.  
Demographic factors Age 
 Sex 
 Ethnicity 
 Socio–economic status  
Health behaviors Smoking  
 Physical activity 
 Alcohol intake 
Blood pressure Systolic blood pressure 
 Diastolic blood pressure 
 Hypertension 
Cholesterol Total cholesterol 
 Low–density lipoprotein cholesterol  
 High–density lipoprotein cholesterol 
 Triglycerides 
Metabolic Diabetes mellitus 
 Renal function 
Anthropometry Height 
 Weight 
 Body Mass Index 
Inflammation C–reactive protein 
 Fibrinogen 
 Thyroid function  
 Autoimmune diseases 
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Table 2.  
     AF ascertainment: Factors included in review:                                  
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consented observational  / health screening cohorts  
WHI–OS United States 50–79 81317 100 11.5 ○ ● ○ 9792 ○ ○ ○ ○ ○ ○ ● ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ (27) 
    50–79 81892 100 9.8 ○ ● ○ 8252 ● ○ ● ● ● ● ○ ○ ○ ● ○ ○ ○ ○ ● ○ ○ ○ ● ○ ○ ○ ○ (28) 
COSM Sweden 45–79 44410 0 12.0 ○ ● ○ 4568 ○ ○ ○ ○ ○ ○ ● ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ (29) 
    45–83 43841 0 10.9 ○ ● ○ 4488 ○ ○ ○ ○ ○ ● ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ (16) 
NPMS Japan 20–NR 223877 68 5.9 ● ○ ○ 2974 ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ● ○ ○ ○ ○ ○ ○ ○ (30) 
    20–NR 28449 66 4.5 ● ○ ○ 265 ○ ○ ○ ○ ○ ○ ○ ○ ○ ● ○ ○ ○ ○ ○ ○ ○ ○ ● ○ ○ ○ ○ (31) 
    20–NR 28449 66 4.5 ● ○ ○ 265 ● ○ ○ ○ ○ ○ ○ ○ ○ ○ ● ● ● ● ○ ○ ○ ○ ○ ○ ○ ○ ○ (32) 
SMC Sweden 49–83 36513 100 12.0 ○ ● ○ 2915 ○ ○ ○ ○ ○ ○ ● ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ (33) 
    45–83 35178 100 10.9 ○ ● ○ 2757 ○ ○ ○ ○ ○ ● ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ (16) 
DCHS Denmark 50–64 55273 52 13.5 ○ ● ○ 2581 ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ● ● ● ○ ○ ○ ○ (34) 
    50–64 47589 53 5.7 ○ ● ○ 553 ● ○ ○ ● ● ● ○ ● ○ ● ● ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ (35) 
    50–64 38400 49 5.7 ○ ● ○ 418 ○ ○ ○ ○ ○ ○ ● ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ (36) 
MPP Sweden 26–61 30865 32 23.3 ○ ● ○ 2312 ● ● ○ ○ ● ○ ○ ○ ○ ● ○ ○ ○ ○ ● ○ ○ ○ ● ○ ○ ○ ○ (37) 
ARIC United States 45–64 14352 55 20.6 ● ● ○ 1794 ○ ○ ○ ● ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ (38) 
    45–64 14219 55 18.2 ● ● ○ 1775 ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ● ○ ○ ○ ○ (39) 
    45–64 14598 55 17.1 ● ● ○ 1520 ○ ○ ○ ○ ● ○ ○ ○ ○ ● ○ ○ ○ ○ ● ○ ○ ○ ○ ○ ○ ○ ○ (40) 
    45–64 13969 55 18.7 ● ● ○ 1433 ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ● ● ● ● ○ ○ ○ ○ ○ ○ ○ ○ ○ (41) 
    45–64 14858 55 16.8 ● ● ○ 1209 ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ● ○ ○ ○ (42) 
    45–65 15407 55 14.8 ● ● ○ 1085 ● ● ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ (43) 
    45–64 14419 55 16.0 ● ● ○ 1068 ○ ○ ● ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ (44) 
    45–64 10328 57 10.1 ○ ● ○ 788 ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ● ○ ○ ○ ○ ○ ○ ○ (45) 
    45–64 14546 55 NR ● ● ○ 515 ○ ○ ○ ○ ○ ● ● ● ● ○ ○ ○ ○ ○ ○ ○ ○ ● ○ ○ ○ ○ ○ (46) 
    46–94 10675 57 NR ● ● ○ 419 ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ● ○ ○ ○ ○ ○ ○ (47) 
CHS United States 65–89 5685 58 11.2 ● ● ○ 1585 ○ ○ ○ ● ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ● ○ ○ ○ ○ (48) 
    65–NR 5365 57 10.0 ● ● ○ 1172 ○ ○ ● ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ (44) 
    65–NR 5446 58 8.7 ● ● ○ 1061 ○ ○ ○ ○ ○ ○ ● ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ (49) 
    65–NR 5491 45 6.9 ● ● ● 897 ● ● ○ ○ ○ ○ ○ ● ● ● ○ ○ ○ ○ ● ○ ○ ○ ○ ○ ● ○ ○ (50) 
    65–NR 2673 56 NR ● ● ○ 812 ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ● ○ (51) 
    65–NR 5043 60 NR ● ● ○ 624 ○ ○ ○ ○ ● ○ ○ ○ ○ ○ ○ ● ○ ● ○ ○ ● ○ ○ ○ ○ ○ ○ (47) 
    65–NR 4321 59 7.4 ● ● ● 579 ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ● ○ ○ ○ ○ ○ ○ ○ (52) 
    65–NR 4844 58 3.3 ● ● ● 304 ○ ○ ○ ○ ○ ● ○ ○ ○ ○ ● ○ ○ ○ ○ ○ ○ ● ○ ○ ○ ○ ○ (53) 
MDCS Sweden 44–73 30441 60 11.2 ○ ● ○ 1430 ○ ○ ○ ○ ● ○ ○ ○ ○ ○ ○ ○ ○ ○ ● ○ ○ ○ ○ ○ ○ ○ ○ (54) 
    41–71 5135 59 14.0 ○ ● ○ 284 ● ● ○ ○ ○ ○ ○ ● ● ● ○ ○ ● ○ ○ ○ ○ ○ ● ○ ● ○ ○ (55) 
GPPS Sweden 47–56 6903 0 NR ○ ● ○ 1253 ○ ○ ○ ● ● ○ ● ● ○ ● ● ○ ○ ○ ● ○ ○ ● ● ○ ○ ○ ○ (56) 
IPHS Japan 40–79 132250 69 13.8 ● ○ ○ 1232 ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ● ○ ○ ○ ○ ○ ○ ○ (57) 
WHS United States 45–NR 33372 100 16.4 ● ● ○ 1027 ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ● ○ ○ ○ ○ ○ ○ ○ ○ (58) 
    45–NR 34759 100 14.4 ● ● ○ 968 ○ ○ ○ ○ ○ ○ ● ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ (59) 
    NR–NR 34309 100 12.9 ● ● ○ 834 ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ● ○ ○ ○ ○ (60) 
    45–NR 23738 100 16.4 ● ● ○ 795 ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ● ● ● ● ○ ○ ○ ○ ○ ○ ○ ○ ○ (61) 
    45–NR 24746 100 15.4 ● ● ○ 786 ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ● ○ ○ ○ ○ ○ ○ ○ (62) 
    45–NR 24734 100 14.4 ● ● ○ 747 ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ● ● ○ ○ (63) 
    45–NR 34715 100 12.4 ● ● ○ 653 ○ ○ ○ ○ ○ ● ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ (64) 
    45–NR 34221 100 12.4 ● ● ○ 644 ○ ○ ○ ○ ○ ○ ○ ● ● ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ (65) 
NorPD Norway 40–45 309540 52 NR ○ ● ○ 863 ○ ○ ○ ○ ○ ○ ● ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ (66) 
TS Norway 25–NR 22815 52 11.1 ○ ● ○ 822 ● ○ ○ ○ ○ ○ ○ ○ ○ ● ● ● ○ ○ ● ○ ○ ● ● ○ ○ ○ ○ (67) 
  25–84 6315 51 10.9 ○ ● ○ 566 ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ● ● ○ ○ (68) 
FHS United States 35–91 5331 55 16.0 ● ○ ○ 698 ○ ○ ○ ○ ○ ○ ○ ● ● ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ (69) 
    45–95 4764 55 NR ● ○ ○ 457 ● ● ○ ○ ● ● ○ ○ ○ ● ○ ○ ○ ○ ● ○ ○ ● ● ○ ○ ○ ○ (70) 
    30–87 2608 56 11.9 ● ○ ○ 259 ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ● ● ● ● ○ ○ ○ ○ ○ ○ ○ ○ ○ (71) 
    60–NR 2007 59 NR ● ○ ○ 192 ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ● ○ (72) 
    NR–NR 2863 55 6.2 ● ● ○ 148 ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ● ● ○ ○ (73) 
    46–94 2838 55 NR ● ○ ○ 143 ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ● ● ○ ○ ○ ○ ○ ○ (47) 
MCS Sweden 26–61 6031 0 25.0 ○ ● ○ 667 ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ● ○ ○ ○ (74) 
AGES Iceland 46–94 4469 60 NR ● ● ○ 408 ● ● ○ ○ ● ○ ○ ● ● ● ● ● ○ ● ● ● ● ● ○ ○ ○ ○ ○ (47) 
    45–95 4467 60 NR ● ● ○ 408 ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ● ○ ○ (75) 
    45–95 4238 63 4.2 ○ ● ○ 226 ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ● ○ ○ ○ ○ (76) 
p 28 (28) 
     AF ascertainment: Factors included in review:                                  
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RS Netherlands 45–NR 9166 57 6.8 ● ● ○ 402 ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ● ○ (77) 
    55–NR 5668 65 7.2 ● ● ○ 371 ○ ○ ○ ○ ● ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ (78) 
    55–NR 3203 59 NR ● ● ○ 177 ● ● ○ ○ ○ ○ ○ ● ● ● ● ● ○ ● ● ● ● ● ○ ○ ○ ○ ○ (47) 
    45–95 3203 59 NR ● ● ○ 177 ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ● ○ ○ (75) 
CCHS Denmark  40–79 18167 56 NR ○ ● ○ 379 ○ ● ○ ○ ● ● ○ ● ○ ● ○ ○ ○ ○ ● ○ ● ● ● ○ ○ ○ ○ (79) 
    20–NR 8410 58 7.5 ○ ● ○ 268 ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ● ○ ○ ○ (80) 
HABC United States 70–79 2717 52 NR ○ ● ○ 371 ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ● ○ ○ ○ ○ (81) 
    70–79 1850 52 8.1 ● ○ ○ 17 ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ● ○ (82) 
BHS Australia 25–84 4267 56 NR ○ ● ○ 343 ○ ○ ○ ○ ● ● ○ ● ● ○ ● ● ● ● ● ● ○ ○ ● ○ ● ○ ○ (83) 
    18–90 1048 48 20.0 ○ ● ○ 14 ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ● ○ (82) 
MESA United States 45–84 6630 53 7.8 ○ ● ○ 307 ○ ○ ○ ○ ○ ○ ○ ● ● ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ (84) 
    45–84 6721 53 7.0 ○ ● ○ 305 ○ ○ ● ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ (85) 
    45–84 4534 52 8.2 ○ ● ○ 221 ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ● ● ● ● ○ ○ ○ ○ ○ ○ ○ ○ ○ (71) 
    45–84 5793 53 7.7 ○ ● ○ 199 ○ ○ ○ ○ ○ ○ ● ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ (86) 
    45–84 5311 53 5.3 ○ ● ○ 182 ○ ○ ○ ○ ○ ○ ○ ○ ○ ● ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ (87) 
CIRCS Japan 30–80 7206 63 6.4 ● ● ● 296 ● ● ○ ○ ● ● ○ ○ ○ ● ● ○ ○ ○ ● ○ ○ ○ ● ○ ○ ○ ○ (88) 
S–HS Sweden 60–60 4021 52 13.6 ○ ● ○ 285 ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ● ● ● ○ ○ ○ ○ (89) 
OCS Norway 40–59 1997 0 30.0 ● ● ○ 270 ● ○ ○ ○ ○ ○ ● ● ● ○ ○ ○ ○ ○ ○ ○ ○ ○ ● ○ ○ ○ ○ (90) 
TSS Japan 30–84 8360 53 12.8 ● ● ● 253 ○ ○ ○ ○ ○ ○ ○ ● ● ● ○ ○ ○ ○ ○ ○ ○ ○ ● ○ ○ ○ ○ (91) 
L85PS Netherlands 85–85 420 64 5.2 ● ○ ○ 39 ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ● ○ (82) 
SHIP Germany  20–81 2891 47 10.1 ● ○ ○ 34 ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ● ○ (82) 
                      Participants:  1112394            AF events: 39900                         
administrative / electronic health records cohorts  
HCUP United States 18–NR 13967949 57 3.2 ○ ● ○ 375318 ○ ○ ● ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ (92) 
D–EHR Denmark 16–NR 4182335 51 4.8 ○ ● ○ 156484 ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ● (93) 
    10–NR 4518484 49 9.2 ○ ● ○ 126217 ● ● ○ ● ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ● ○ ○ ○ ○ ○ ○ ● (94) 
    18–100 5081087 45 NR ○ ● ○ 115956 ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ● ○ ○ ○ ○ ○ ○ ○ ○ (95) 
    18–NR 586460 61 5.5 ○ ● ○ 17154 ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ● ○ (96) 
S–EHR Sweden 00–95 170368 62 10.4 ○ ● ○ 3859 ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ● (97) 
T–NHIRD Taiwan 18–NR 88377 61 NR ○ ● ○ 1041 ● ● ○ ○ ○ ○ ○ ○ ○ ● ○ ○ ○ ○ ● ● ○ ○ ○ ○ ○ ○ ○ (98) 
                    Participants: 19307781            AF events:  536702                          
                       Total participants: 20420175 Total AF events: : 576602                         
Table 2 legend: AF – atrial fibrillation, HDL – high–density lipoprotein cholesterol, LDL – low–density lipoprotein 
cholesterol, ● – yes, ○ – no. Cohort abbreviations: WHI–OS – Women's Health Initiative Observational Study, COSM – 
Cohort of Swedish Men, NPMS – Niigata preventive medicine study, SMC – Swedish Mammography Cohort, DCHS – Diet 
Cancer and Health study, MPP – Malmö Preventive Project, ARIC – Atherosclerosis Risk in Communities, CHS – 
Cardiovascular Health Study, MDCS – Malmö Diet and Cancer study, GPPS – Göteborg Primary Prevention Study, IPHS 
– Ibaraki prefectural health study, WHS – Women's Health Study, NorPD – Norwegian Prescription Database, TS – 
Tromsø Study, FHS – Framingham Heart Study, MCS – Malmö Cardiovascular Screening, AGES – Age, Gene and 
Environment–Reykjavik study, RS – Rotterdam Study , CCHS – Copenhagen City Heart Study, HABC – Health, Aging, 
and Body Composition, BHS – Busselton Health Study, MESA – Multi–Ethnic Study of Atherosclerosis, CIRCS – 
Circulatory Risk in Communities Study, S–HS – Stockholm Health Screening cohort , OCS – Oslo Cardiovascular Survey, 
TSS – The Suita Study, L85PS – Leiden 85–Plus Study, SHIP – Study of Health in Pomerania, HCUP – Healthcare Cost 
and Utilization Project, D–EHR – Denmark Electronic Health Record cohort, S–EHR – Sweden Electronic Health Record 
cohort, T–NHIRD – Taiwan National Health Insurance Research Database. 
 
